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Objectives: Chronic obstructive pulmonary disease (COPD) is one of the main late  complications 
of sulfur mustard poisoning. The aim of this study was to evaluate serum levels of interleukin 
(IL)-6 in war veterans with pulmonary complications of sulfur mustard poisoning and their cor-
relation with severity of airways disease.
Methods: Fifty consecutive patients with sulfur mustard poisoning and stable COPD, and of mean 
age 46.3 ± 9.18 years were enrolled in this study. Thirty healthy men were selected as controls 
and matched to cases by age and body mass index. Spirometry, arterial blood gas,  six-minute 
walk test, BODE (body mass index, obstruction, dyspnea, and exercise capacity), and St George’s 
Respiratory Questionnaire about quality of life were evaluated. Serum IL-6 was measured in 
both patient and control groups.
Results: Fifty-four percent of patients had moderate COPD. Mean serum IL-6 levels were 
15.01 ± standard deviation (SD) 0.61 pg/dL and 4.59 ± 3.40 pg/dL in the case and control groups, 
respectively (P = 0.03). There was a significant correlation between IL-6 levels and Global 
Initiative for Chronic Obstructive Lung Disease stage (r = 0.25, P = 0.04) and between IL-6 
and BODE index (r = 0.38, P = 0.01). There was also a significant negative correlation between 
serum IL-6 and forced expiratory volume in one second (FEV
1
, r = −0.36, P = 0.016).
Conclusion: Our findings suggest that serum IL-6 is increased in patients with sulfur mustard 
poisoning and COPD, and may have a direct association with airflow limitation.
Keywords: sulfur mustard, chronic obstructive pulmonary disease, interleukin-6, inflamma-
tion, chemical warfare
Introduction
Sulfur mustard used as a toxic chemical gas can cause serious ocular, neurologic, 
cutaneous, bone marrow, and pulmonary complications.1 Sulfur mustard was used 
as a chemical warfare agent during the Iran–Iraq war between 1983 and 1988, and 
approximately 45,000 patients are now suffering from the late complications of sulfur 
mustard poisoning,1,2 with high morbidity.3
The most common late complications of sulfur mustard poisoning are respiratory 
problems, including chronic obstructive pulmonary disease (COPD), chronic bronchitis, 
bronchiolitis obliterans, bronchiectasis, airway hyperreactivity, and lung fibrosis.4–8
COPD is a condition characterized by poorly reversible airflow limitation that is 
usually progressive and associated with an abnormal inflammatory response of the lungs 
to noxious agents.9 It is now well documented that the inflammatory response in COPD 
is not limited to the lungs, and also that systemic inflammation plays an important role 
in its presentation. Inflammatory markers, such as C-reactive protein (CRP), interleukin 
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(IL)-6, and tumor necrosis factor alpha, are also important in 
the pathogenesis of COPD, and raised levels of these factors 
have been found in stable COPD patients.10–12
IL-6 as a proinflammatory cytokine may play a consider-
able role in the systemic inflammatory response in COPD.13,14 
Several different cell types can produce IL-6, but the main 
sources are monocytes, macrophages, T and B cells, fibro-
blasts, epithelial cells, and the smooth muscle cells of the 
airways.14
It has been shown that high levels of serum or sputum 
IL-6 are associated with impaired lung function or a faster 
decline in lung function,13,15 independent of confounders such 
as age and smoking.10 In addition, elevated serum levels of 
IL-6 have been associated with dyspnea, skeletal muscle 
weakness, pulmonary arterial hypertension, and COPD 
exacerbations.10,15–17
There have been few studies of the role of systemic 
inflammation in late pulmonary complications of sulfur 
mustard exposure in chemical warfare veterans. Although 
some of these studies confirm the inflammatory basis of the 
illness,18,19 there are some controversies about it.20 The pres-
ent study was designed to evaluate the correlation between 
serum IL-6 and important clinical and paraclinical severity 
factors in nonsmoking patients with pulmonary complica-
tions of sulfur mustard poisoning.
Materials and methods
Between April and September 2008, 50 chemical warfare vet-
erans with stable COPD who attended the pulmonary clinic of 
Ghaem hospital, Mashhad, Iran, were entered into this cross-
sectional study. All subjects were nonsmoking males who had 
validated documentation of sulfur mustard gas exposure and 
experienced symptoms after sulfur mustard poisoning. Thirty 
nonsmoking healthy men with no history of pulmonary or 
inflammatory diseases were enrolled as a control group, and 
their age and body mass index (BMI) were matched to the 
subjects. Time since sulfur mustard exposure ranged from 19 
to 23 years. Patients with all levels of COPD severity were 
included in the study if they had a forced expiratory volume 
in one second (FEV
1
) to forced vital capacity (FVC) ratio 
of ,0.7 after 400 µg of inhaled albuterol, according to the 
definition of the American Thoracic Society.21
Patients were excluded if their FEV
1
 increased by more 
than 12% and 200 mL after a bronchodilator, or if they 
had asthma, bronchiectasis, tuberculosis, active pulmonary 
infection, cardiovascular disease, diabetes mellitus, or other 
confounding inflammatory diseases, such as malignancy, 
arthritis, connective tissue disease, and inflammatory bowel 
disease, or if they had had an exacerbation of disease or 
hospitalization during the previous two months.
One chest physician visited all the subjects. Weight (with 
clothes on) and height (without shoes) were measured for 
each participant, and BMI was calculated as weight (kg) 
divided by height (m) squared. The St George’s Respiratory 
Questionnaire (SGRQ) about quality of life was completed 
for all of the patients.22 The validated and reliable Farsi ver-
sion of the SGRQ was used.23 Symptoms, activity, impact, 
and total scores were calculated for each patient using an 
Excel-based scoring calculator.22
FEV
1
, FVC, and FEV
1
/FVC were measured by standard 
spirometric techniques (Multi-Functional Spirometer HI-801; 
Chest MI Inc., Tokyo, Japan) and the results were expressed 
as a percentage of the predicted values. The best of three 
consecutive recordings of spirometry was used. The severity 
of COPD was assessed using FEV
1
 measurement based on 
the GOLD (Global Initiative for Chronic Obstructive Lung 
Disease) guideline,9 ie: Stage 1 (mild) FEV
1
/FVC , 70%, 
FEV
1
 . 80%; Stage 2 (moderate) FEV
1
/FVC , 70%, 
50% # FEV
1
 , 80%; Stage 3 (severe) FEV
1
/FVC , 
70%, 30% # FEV
1
 , 50%; and Stage 4 (very severe) FEV
1
/
FVC , 70%, FEV
1
 , 30%.
The BODE (body mass index, obstruction, dyspnea, and 
exercise capacity) index was calculated in all patients with 
total possible values in the range 0–10.24 Dyspnea was evalu-
ated by the Modified Medical Research Council scale,24 which 
was graded between 0–4 according to the patient’s complaint. 
Finally, the patients performed the 6-minute walk test (6MWT) 
according to American Thoracic Society guidelines.25
Blood samples
Nonfasting blood samples were obtained from the antecu-
bital vein at rest. Serum IL-6 was measured by the Bender 
MedSystem Human IL-6 (BMS 213/2; Medical System 
 Diagnostic GmBH, Austria, test sensitivity 1.4 pg/mL). The 
samples were identified by bar code, so that samples from 
controls and COPD patients were randomly distributed 
among the assay plates. Arterial blood gases were measured 
by a blood gas analyzer (AVL 995; AVL Scientific Corpora-
tion, Roswell, GA). The study was approved by the Ethics 
Committee of the Mashhad University of Medical Sciences. 
All patients gave informed consent.
statistical analysis
The data were analyzed using the Statistical Package for Social 
Sciences (Version 14.0; SPSS Inc., Chicago, IL) by a medical 
 statistician (MK). The variables are presented as percentages 
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and means ± standard deviations. Descriptive statistics were 
used to summarize the demographic characteristics of the case 
and control groups. The normality of continuous variables was 
checked using the one-sample Kolmogorov–Smirnov test. For 
continuous and categoric variables, independent Student’s 
t-tests and Chi-square tests were used to evaluate the statistical 
significance of any difference or relationship between the 
study parameters, respectively. Pearson and Spearman 
correlation coefficients were calculated. P values less than 
0.05 were considered significant.
Results
The mean age of the patients was 46.3 ± 9.18 years, with a 
BMI of 27.32 ± 3.30 kg/m2. The majority of patients were 
in the moderate to severe stages of GOLD (54% and 24%, 
respectively, Figure 1). The mean age and BMI of controls 
were 47.8 ± 7.9 years and 27.2 ± 2.1, respectively. The char-
acteristics of the subjects are shown in Table 1.
When serum levels of IL-6 were assessed in the two groups, 
it was found that the difference was  statistically significant, 
and the mean serum level of IL-6 was higher in patients than 
in controls (15.01 ± 0.61 versus 4.59 ± 3.40 pg/dL, respec-
tively, P = 0.03, Figure 2).
The correlations between IL-6 and potential parameters of 
COPD severity in the patients were examined and are shown 
in Table 2. There was a significant correlation between FEV
1
 
percent predicted and serum IL-6 (r = −0.36, P = 0.016) as 
illustrated in Figure 3; in other words, the higher the serum 
level of IL-6, the lower level of FEV
1
. Statistically signifi-
cant correlations were also found between IL-6 and GOLD 
(r = 0.25, P = 0.04), and 6MWT (r = −0.02, P = 0.02).
Of 50 patients, 28 (56%) had BODE scores $4. The 
correlation between serum IL-6 and BODE index was 
 statistically significant (r = 0.38, P = 0.01), as shown in 
Figure 4, which means that higher levels of serum IL-6 were 
associated with higher BODE index scores.
Comparison of serum IL-6 between patients who were on 
inhaled corticosteroids and those who were not did not show 
any statistically significant difference (P = 0.12).
Discussion
The purpose of this study was to evaluate the relationship 
between serum IL-6 levels as an inflammatory marker and 
lung function parameters in chemical warfare patients with 
COPD as a late pulmonary complication of sulfur mustard 
poisoning. We found that serum levels of IL-6 were signifi-
cantly higher in patients than in controls, and statistically 
significant correlations were present between serum IL-6 
and FEV
1
 percent predicted, GOLD stage, BODE index, and 
6MWT in this group of patients.
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Figure 1 The frequency of gOLD stages in 50 chemical warfare patients with 
chronic obstructive pulmonary disease as a late pulmonary complication of sulfur 
mustard poisoning. 
Abbreviation: gOLD, global Initiative for Chronic Obstructive Lung Disease.
Table 1 Demographic and clinical parameters of lung function in 
50 patients with chronic obstructive pulmonary disease as a late 
pulmonary complication of sulfur mustard poisoning
Parameters Values
Age (years) 46.3 ± 9.18
Duration of disease (years) 17.00 ± 6.00
FeV1 (% predicted) 58.98 ± 17.51
FeV1/FVC 62.14 ± 9.70
6MWT (minutes) 327.8 ± 86.96
BMI 27.32 ± 3.30
PaO2 (mmhg) 75.1 ± 12.00
saO2 (%) 94.03 ± 3.45
PaCO2 (mmhg) 37.55 ± 9.50
Total sgrQ score 56.23 ± 14.31
IL-6 (pg/mL) 15.01 ± 0.61
Inhaled corticosteroid therapy (% of patients) 42
Note: The data are presented as the mean ± sD. 
Abbreviations: FeV1, forced expiratory volume in one second; FVC, forced vital 
capacity; 6MWT, 6-minute walk test; BMI, body mass index; PaO2, arterial oxygen 
tension; saO2, arterial oxygen saturation; PaCO2, arterial carbon dioxide tension; sgrQ, 
st george’s respiratory Questionnaire; IL-6, interleukin-6; sD, standard deviation.
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Figure 2 Comparison of serum interleukin-6 between patients and controls. 
Abbreviation: IL-6, interleukin 6.
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As mentioned earlier, COPD is now considered to be a 
systemic inflammatory condition. The pathogenesis of COPD 
is mainly dependent on chronic inflammation and also oxidative 
stress following activation of airway  inflammatory cells.26,27 
Oxidative stress may not only  damage the airways directly, but 
may also trigger inflammatory events in the respiratory tract.28 
The production of various inflammatory biomarkers is the result 
of chronic inflammation in COPD,28,29 which has an important 
role in systemic COPD  comorbidities.30 IL-6 is known to be 
a significant  inflammatory marker in COPD, which has an 
important part in reduced FEV
1
, impaired functional capacity, 
dyspnea, exacerbations, and disturbed functional capacity.11,17 
IL-6 also accelerates the release of acute-phase proteins and 
worsens the  underlying inflammatory condition.31
Despite the apparent inflammatory basis of COPD, 
the exact role of inflammation in the pathogenesis of late 
pulmonary complications of sulfur mustard poisoning is 
not clear. A recent pathologic study in patients with sulfur 
mustard poisoning revealed that bronchiolar disease with 
varying degrees of inflammation is the main pathologic 
finding in these patients.32 It seems that a neutrophil- and/or 
 lymphocyte-predominant inflammatory process may be 
involved in the late pulmonary complications of sulfur mus-
tard poisoning,33,34 and generation of reactive oxygen species 
by inflammatory cells results in oxidative stress.33 Shohrati 
et al showed that decreased glutathione and increased serum 
malondialdehyde levels in patients with late pulmonary 
complications of sulfur mustard exposure to be an indicator 
of imbalance in the oxidative-antioxidative system.34 Their 
finding was compatible with that of previous animal studies 
of sulfur mustard pulmonary injuries.35,36 The oxidative-
antioxidative imbalance may result in oxidative stress37 and, 
as mentioned earlier, oxidative stress has an important role 
in the inflammatory process.
On the other hand, it is well accepted that cytokines play 
an important part in early pulmonary complications of sulfur 
mustard exposure, but there are limited studies of the level of 
cytokines in the late phase of the disease.20 Increased levels 
of IL-8 in the bronchoalveolar lavage fluid of patients with 
sulfur mustard poisoning and late pulmonary complications 
have been demonstrated.18 Also, in our previous study, we 
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Figure 3 Correlation of serum IL-6 and FeV1 percent predicted (r = −0.36, P = 0.016). 
Abbreviations: IL-6, Interleukin 6; FeV1, forced expiratory volume in one second.
Table 2 Correlation of serum interleukin-6 with lung function 
parameters in 50 patients with late pulmonary complications of 
sulfur mustard poisoning
Variable Correlation 
coefficient (r)
P value
Age 0.06 0.71
BMI 0.21 0.16
Duration of disease 0.70 0.60
FeV1 (% predicted) −0.36 0.016
gOLD 0.25 0.04
PaO2 −0.06 0.70
PaCO2 0.08 0.61
MMrC 0.17 0.27
6MWT −0.02 0.02
BODe 0.38 0.01
Total sgrQ score 0.90 0.23
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in one 
second; gOLD, global Initiative for Chronic Obstructive Lung Disease; PaO2, 
arterial oxygen tension; PaCO2, arterial carbon dioxide tension; MMRC, Modified 
Medical research Council; 6MWT, 6-minute walk test; BODe, body mass index, 
obstruction, dyspnea, and exercise capacity; sgrQ, st george’s respiratory 
Questionnaire.
IL
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Figure 4 Correlation of serum interleukin-6 and BODe index (r = 0.38, P = 0.01). 
Abbreviations: IL-6, Interleukin 6; BODe, Body mass index, Obstruction, Dyspnea, 
exercise.
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concluded that serum levels of highly sensitive C-reactive 
protein (hs-CRP), as an inflammatory marker, are elevated 
in patients with sulfur mustard poisoning and are correlated 
inversely with FEV
1
.19 Shohrati et al verified a minimal asso-
ciation between pulmonary function parameters and serum 
levels of glutathione and malondialdehyde.33 Despite these 
studies, Pourfarzam et al believed that inflammatory media-
tors probably do not have any major role in the pathogenesis 
and persistence of pulmonary complications of sulfur mustard 
exposure.20 In our study, even with the exclusion of smok-
ing, as well as inflammatory and systemic disorders, serum 
levels of IL-6 were significantly higher in patients than in 
controls. This finding provides evidence of the possibility of 
an inflammatory basis for the late pulmonary complications 
of sulfur mustard exposure and is in accordance with previous 
studies in other COPD patients which pointed out that, even 
during the stable phase of COPD, serum levels of inflamma-
tory markers, including IL-6, may be raised.11,12
Our results showed that serum levels of IL-6 were 
increased significantly by progression of airways disease 
severity evaluated by GOLD stages. The BODE index is a 
more reliable parameter of COPD morbidity and mortality,24 
and was significantly correlated with the serum IL-6 level. 
These findings are compatible with previous studies in COPD 
patients. A similar association of serum hs-CRP levels and 
GOLD stage was found in our previous study.19 The pos-
sibility of an inflammatory background for the severity of 
airway disease, as in patients with COPD due to smoking, 
is strengthened by these results.
Previous research in COPD patients has revealed that 
the serum IL-6 level is an independent predictor of exercise 
tolerance.38 Similarly, our findings showed that higher serum 
levels of IL-6 are associated with more impaired exercise 
tolerance in patients assessed by 6MWT. Therefore, the 
underlying inflammatory basis of lung disease attributable to 
sulfur mustard exposure may have a direct impact on the 
patient’s functioning which adversely influences their quality 
of life. Also, the SGRQ was shown to be a valid tool for the 
evaluation of quality of life in these patients. Our results are 
compatible with previous studies of impaired function and 
quality of life in chemical warfare patients.19,39
There was no statistically significant difference between 
patients who took inhaled steroids and those who did not. 
There is limited evidence to suggest that inhaled corticosteroids 
can modify systemic inflammation in COPD.40 In a study by 
Sin et al inhaled corticosteroids alone or in combination with 
a beta-agonist did not reduce serum CRP and IL-6 levels in 
patients with moderate to severe COPD, but did decrease 
serum surfactant-D protein levels.40,41 They  suggested that 
inhaled corticosteroids can reduce lung-specific, but not gen-
eralized, biomarkers of systemic inflammation in COPD.40 The 
overall modest anti-inflammatory effects of corticosteroids in 
COPD, irrespective of their route of administration, is another 
explanation for this effect.41 The limitations of our study 
include its small sample size and lack of comparison of our 
findings with those in patients with COPD due to smoking.
In conclusion, serum levels of IL-6 are raised in chemical 
warfare veterans with pulmonary complications due to sulfur 
mustard exposure, and this inflammatory marker has a direct 
correlation with severity of airways disease.
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